About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Conference & CLE Calendar | Main | Amgen Survives Another EPO Challenge »

October 28, 2007

ARYx Therapeutics Inc. Sets Terms of IPO in Regulatory Filing with SEC

    By Christopher P. Singer --

Aryx_logo As reported last Tuesday, October 23, 2007, ARYx Therapeutics set its planned initial public offering at 5 million shares for an estimated price of $14 to $16 each.  In the filing, ARYx indicated that Morgan Stanley, CIBC World Markets, Jefferies & Co, and Leerink Swann were underwriting the IPO.  At that price point, the company anticipates to raise about $67.8 million in proceeds after expenses.  The underwriters have the option to buy an additional 750,000 shares to cover over-allotments.  ARYx plans to list its stock on the Nasdaq under the symbol "ARYX".

ARYx has several drug candidates in clinical Phase II testing, which are based on its RetroMetabolic "ARM" technology.  This approach seeks to identify and design an "ideal metabolite" which is non-toxic, water soluble, and pharmacologically inactive and is not metabolized through a typical metabolic pathway.  This strategy avoids any metabolic "bottlenecks" and associated build-up of drug levels.

Posted at 11:02 PM in Biotech/Pharma Business |

Comments

The comments to this entry are closed.

October 2024

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Categories

Archives

More...